Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

5HT3 Antagonism and Auditory Gating in Schizophrenia

This study has been completed.
Sponsor:
Information provided by:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT00018850
First received: July 3, 2001
Last updated: January 20, 2009
Last verified: December 2004
  Purpose
The target groups in this study are brain waves and neurotransmitters (chemical messengers) in the brain. Subjects with diagnosed with schizophrenia will be studied. The study will help understand more about normal brain functioning and how that functioning differs in people with schizophrenia. Another purpose of this study is to determine how the altered brain functioning in schizophrenia contributes the symptoms found in the illness.

Condition Intervention
Schizophrenia
Drug: ondansetron
Behavioral: neuropsychological testing
Drug: nicotine
Drug: haloperidol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: 5HT3 Antagonism and Auditory Gating in Schizophrenia

Resource links provided by NLM:


Further study details as provided by VA Office of Research and Development:

Study Start Date: June 1998
Estimated Study Completion Date: June 2003
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Subjects with diagnosed with schizophrenia will be studied.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018850

Locations
United States, Colorado
VAMC
Denver, Colorado, United States, 80013
Sponsors and Collaborators
VA Office of Research and Development
  More Information

ClinicalTrials.gov Identifier: NCT00018850     History of Changes
Other Study ID Numbers: MHBS-013-99F 
Study First Received: July 3, 2001
Last Updated: January 20, 2009
Health Authority: United States: Federal Government

Keywords provided by VA Office of Research and Development:
schizophrenia
ondansetron
nicotine
haloperidol

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Nicotine
Ondansetron
Haloperidol
Haloperidol decanoate
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antiemetics
Gastrointestinal Agents
Antipruritics
Dermatologic Agents
Serotonin Antagonists
Serotonin Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Anti-Anxiety Agents
Dopamine Antagonists
Dopamine Agents
Anti-Dyskinesia Agents

ClinicalTrials.gov processed this record on September 23, 2016